But the Galaxies Lung-201 trial features notable omissions, plus toxicity.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.